INITIAL ASSESSMENT OF REAL-WORLD USAGE OF EXTENDED-RELEASE INJECTABLE PALIPERIDONE PALMITATE AMONG MEDICAID INSURED SCHIZOPHRENIA PATIENTS

被引：0
|
作者：
Kamat, S. [1 ]
Gutierrez, B. [1 ]
Eramo, A. [2 ]
Zubek, D. [1 ]
Baker, R. A. [3 ]
Lin, J. [4 ]
Karson, C. [5 ]
机构：
[1] Otsuka Amer Pharmaceut Inc, Princeton, NJ USA
[2] H Lundbeck & Co AS, Copenhagen, Denmark
[3] Otsuka Pharmaceut Dev & Commercializat Inc, Princeton, NJ USA
[4] Novosys Hlth, Flemington, NJ USA
[5] CNK Consulting, Wayne, PA USA
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 03期
关键词：
D O I：
10.1016/j.jval.2013.03.1580
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A61 / A61
页数：1
相关论文
共 50 条
  • [21] Sleep assessments in patients with schizophrenia following treatment with paliperidone extended-release tablets
    Luthringer, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S224 - S224
  • [22] Efficacy of paliperidone extended-release tablets in patients with schizophrenia and predominant negative symptoms
    Dirks, B.
    Eerdekens, M.
    Turkoz, I.
    Alberio, R.
    Gharabawi, G.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S162 - S162
  • [23] Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms
    Canuso, Carla M.
    Turkoz, Ibrahim
    Sheehan, John J.
    Bossie, Cynthia A.
    JOURNAL OF AFFECTIVE DISORDERS, 2010, 120 (1-3) : 193 - 199
  • [24] Intramuscular Administration of Paliperidone Palmitate Extended-Release Injectable Microsuspension Induces a Subclinical Inflammatory Reaction Modulating the Pharmacokinetics in Rats
    Darville, Nicolas
    van Heerden, Marjolein
    Vynckier, An
    De Meulder, Marc
    Sterkens, Patrick
    Annaert, Pieter
    Van den Mooter, Guy
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2014, 103 (07) : 2072 - 2087
  • [25] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Cai, Qian
    Patel, Charmi
    Kim, Edward
    Connolly, Nancy
    Tunceli, Ozgur
    El Khoury, Antoine C.
    ADVANCES IN THERAPY, 2019, 36 (04) : 858 - 869
  • [26] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Qian Cai
    Charmi Patel
    Edward Kim
    Nancy Connolly
    Ozgur Tunceli
    Antoine C. El Khoury
    Advances in Therapy, 2019, 36 : 858 - 869
  • [27] Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
    Kishi, Taro
    Sakuma, Kenji
    Iwata, Nakao
    TRANSLATIONAL PSYCHIATRY, 2022, 12 (01)
  • [28] The social functional outcome of being naturalistically treated with paliperidone extended-release in patients with schizophrenia
    Nakagawa, Ryoko
    Ohnishi, Takashi
    Kobayashi, Hisanori
    Wakamatsu, Akihide
    Tanimura, Ai
    Morita, Kazuo
    Yamaoka, Toshio
    Usui, Hideo
    Ogawa, Yoshimasa
    Fujino, Akiko
    Yoshizawa, Kazutake
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2015, 11 : 1511 - 1521
  • [29] Effects of paliperidone extended-release in acutely ill schizophrenia patients with marked to severe illness
    Dirks, Bryan
    Youssef, Eriene A.
    Turkoz, Ibrahim
    Verbanac, John
    Mahmoud, Ramy
    Canuso, Carla
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 82S - 82S
  • [30] Paliperidone extended-release in acutely ill schizophrenia patients with and without predominant negative symptoms
    Dirks, Bryan
    Bossie, Cyndi
    Turkoz, Ibrahim
    Eederkens, Marielle
    Sherr, Jay
    Mahmoud, Ramy
    Canuso, Carla
    BIOLOGICAL PSYCHIATRY, 2007, 61 (08) : 82S - 82S
12345